NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression - PubMed (original) (raw)
. 2003 Dec 15;9(17):6483-8.
Affiliations
- PMID: 14695152
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression
Katarina Omholt et al. Clin Cancer Res. 2003.
Abstract
Purpose: Recently, it was reported that BRAF mutations are frequent in melanoma. Previously, we analyzed a large series of paired primary and metastatic melanomas for NRAS codon 61 mutations and showed that they arise early and are preserved during tumor progression. Here, we have screened the same tumor samples for BRAF mutations.
Experimental design: Primary melanomas (n = 71) and corresponding metastases (n = 88) from 71 patients were screened for BRAF exon 11 and exon 15 mutations using single-strand conformational polymorphism and nucleotide sequence analysis
Results: BRAF mutations were found in 42 of 71 patients (59%). Thirty-seven patients had mutations that lead to a Val599Glu change, whereas mutations resulting in Gly468Ser, Val599Arg, Val599Lys, and Lys600Glu changes were detected in one patient each. Furthermore, one patient had a 6-bp insertion between codons 598 and 599, encoding two threonine residues. In most cases, paired primary and metastatic lesions had the same BRAF genotype (i.e., mutations present in the primary tumors were preserved in the corresponding metastases, and mutations did not arise at the metastatic stage if they were not present in the primary lesion). Using laser-capture microdissection, BRAF mutations were found in the radial growth phase of the primary lesions. BRAF mutations occurred exclusively in tumors that were wild type for NRAS, and in total, 89% of the patients analyzed (63 of 71) had mutations in either of these two genes.
Conclusions: The Ras-Raf-mitogen-activated protein kinase/extracellular signal-regulated kinase-extracellular signal-regulated kinase signaling pathway is activated in the vast majority of melanomas. Activation occurs through either NRAS or BRAF mutations, both of which arise early during melanoma pathogenesis and are preserved throughout tumor progression.
Similar articles
- BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhönen S, Hemminki K. Kumar R, et al. Clin Cancer Res. 2003 Aug 15;9(9):3362-8. Clin Cancer Res. 2003. PMID: 12960123 - Screening of N-ras codon 61 mutations in paired primary and metastatic cutaneous melanomas: mutations occur early and persist throughout tumor progression.
Omholt K, Karsberg S, Platz A, Kanter L, Ringborg U, Hansson J. Omholt K, et al. Clin Cancer Res. 2002 Nov;8(11):3468-74. Clin Cancer Res. 2002. PMID: 12429636 - BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma.
Colombino M, Capone M, Lissia A, Cossu A, Rubino C, De Giorgi V, Massi D, Fonsatti E, Staibano S, Nappi O, Pagani E, Casula M, Manca A, Sini M, Franco R, Botti G, Caracò C, Mozzillo N, Ascierto PA, Palmieri G. Colombino M, et al. J Clin Oncol. 2012 Jul 10;30(20):2522-9. doi: 10.1200/JCO.2011.41.2452. Epub 2012 May 21. J Clin Oncol. 2012. PMID: 22614978 - Targeting NRAS in melanoma.
Kelleher FC, McArthur GA. Kelleher FC, et al. Cancer J. 2012 Mar-Apr;18(2):132-6. doi: 10.1097/PPO.0b013e31824ba4df. Cancer J. 2012. PMID: 22453013 Review. - The genome and epigenome of malignant melanoma.
Dahl C, Guldberg P. Dahl C, et al. APMIS. 2007 Oct;115(10):1161-76. doi: 10.1111/j.1600-0463.2007.apm_855.xml.x. APMIS. 2007. PMID: 18042149 Review.
Cited by
- Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S. Posch C, et al. Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):4015-20. doi: 10.1073/pnas.1216013110. Epub 2013 Feb 19. Proc Natl Acad Sci U S A. 2013. PMID: 23431193 Free PMC article. - Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations.
Jovanovic B, Egyhazi S, Eskandarpour M, Ghiorzo P, Palmer JM, Bianchi Scarrà G, Hayward NK, Hansson J. Jovanovic B, et al. J Invest Dermatol. 2010 Feb;130(2):618-20. doi: 10.1038/jid.2009.287. Epub 2009 Sep 17. J Invest Dermatol. 2010. PMID: 19759551 Free PMC article. No abstract available. - The intersection of immune-directed and molecularly targeted therapy in advanced melanoma: where we have been, are, and will be.
Sullivan RJ, Lorusso PM, Flaherty KT. Sullivan RJ, et al. Clin Cancer Res. 2013 Oct 1;19(19):5283-91. doi: 10.1158/1078-0432.CCR-13-2151. Clin Cancer Res. 2013. PMID: 24089441 Free PMC article. Review. - Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy.
Mitsiades N, Chew SA, He B, Riechardt AI, Karadedou T, Kotoula V, Poulaki V. Mitsiades N, et al. Invest Ophthalmol Vis Sci. 2011 Sep 14;52(10):7248-55. doi: 10.1167/iovs.11-7398. Invest Ophthalmol Vis Sci. 2011. PMID: 21828154 Free PMC article. - Phytochemicals for the Management of Melanoma.
Pal HC, Hunt KM, Diamond A, Elmets CA, Afaq F. Pal HC, et al. Mini Rev Med Chem. 2016;16(12):953-79. doi: 10.2174/1389557516666160211120157. Mini Rev Med Chem. 2016. PMID: 26864554 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous